KPV

How KPV Is Reported to Act

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Reported activity centres on interference with NF-κB signalling and reduced pro-inflammatory cytokine production. Unlike its parent hormone, KPV's described action is not primarily receptor-mediated. It is small enough to enter cells, which changes what kind of mechanism is plausible.

Key facts

Reported target
NF-κB signalling
Reported effect
Reduced pro-inflammatory cytokines
Melanocortin receptor
Not the primary route described
Size advantage
342 Da (small enough to enter cells)
Model systems
Cell culture and murine models
Human clinical data
None established

What NF-κB does

NF-κB is a transcription factor and one of the central switches of inflammatory signalling. Held inactive in the cytoplasm under normal conditions, it moves to the nucleus when inflammatory signals arrive and drives transcription of cytokines and other inflammatory mediators. Interfering with it affects a broad set of downstream outputs at once.

Why size changes the mechanism question

Alpha-MSH at 1,665 Da acts at cell-surface melanocortin receptors. It is far too large to cross a membrane passively. KPV at 342 Da is a different proposition entirely. A tripeptide of that size can plausibly enter cells, which permits an intracellular mechanism the parent hormone could not have. That is the most interesting structural consequence of the fragment being so short.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

What the models measured

Kannengiesser and colleagues reported anti-inflammatory potential in murine colitis models in 2008. Cell-culture work has examined cytokine production and NF-κB pathway activity. These establish that the compound does something measurable to inflammatory signalling in those systems, which is a statement about those systems.

Why the delivery paper is informative

Xiao and colleagues published on orally targeted delivery of KPV using hyaluronic acid-functionalised nanoparticles in Molecular Therapy in 2017. Researchers do not build targeted delivery systems for compounds that reach their target unaided. The existence of that work tells you the free tripeptide's own delivery to inflamed tissue was the limiting problem.

What is not established

A defined molecular target. NF-κB interference is a described effect rather than a mapped binding interaction, and no receptor or direct binding partner has been characterised. As with several compounds in this library, the downstream consequences are better documented than the initiating event.

And what is not claimed

Nothing about inflammation in people. The work is cell culture and murine models, there is no established human clinical programme, and KPV holds no marketing authorisation anywhere. Colitis models are disease models, not evidence of a treatment.

Frequently asked questions

Does KPV act on melanocortin receptors?

That is not the primary route described. At 342 Da it is small enough for an intracellular mechanism its 1,665 Da parent hormone could not have.

What is NF-κB?

A transcription factor central to inflammatory signalling, driving cytokine production when activated. Interfering with it affects many downstream outputs at once.

Is there human evidence?

No established clinical programme. The literature is cell culture and murine models.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.